PACIFIC BIOSCIENCES OF CALIFORNIA (PACB)
Health Care · genomic sequencing instruments · NASDAQ
PacBio provides high-accuracy, long-read DNA sequencing platforms designed to solve complex genomic challenges for research and clinical applications.
What PACIFIC BIOSCIENCES OF CALIFORNIA does
PacBio is a life science technology company that designs, develops, and manufactures advanced long-read genomic sequencing systems. Its technology enables scientists and clinical researchers to gain comprehensive and accurate insights into genomes, transcriptomes, and epigenomes to address complex genetic challenges in areas such as rare disease, oncology, and infectious disease. The company's platforms are utilized by academic, governmental, and commercial research institutions, as well as hospitals and clinical laboratories.
Recent developments
Mark Van Oene was appointed President and CEO effective August 5, 2026. The company initiated a restructuring plan on July 30, 2026, including an 8% workforce reduction, to align organizational resources with strategic priorities and reduce annual operating expenses by $30-$40 million by end-of-year 2027.
From PACIFIC BIOSCIENCES OF CALIFORNIA's filing of 2026-08-06.
Themes: genomics, AI-driven variant interpretation, clinical sequencing, rare disease diagnostics, oncology research, precision medicine
Fundamentals
- Price$2.30 as of 2026-10-08 close
- Market cap$715M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+52.3% 2025-10-08 close $1.51 → 2026-10-08 close $2.30
- P/En/a negative earnings
- ROE-10214.5% FY2025, SEC XBRL
- Debt / equity272.23 as of 2026-09-02
- Revenue growth (YoY)+2.0% as of 2026-09-02
- Revenue CAGR (3y)-6.9% SEC XBRL
- Beta1.89 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How PACB compares in its sector
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PACIFIC BIOSCIENCES OF CALIFORNIA looks technically
PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) is trading 44.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 127 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago. It is 33.1% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 44.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +44.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.52 | $1.52 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.60 | $1.60 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 1.25. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 127 trading days ago — a "death cross", a bearish long-term signal | 127 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 44.0% above | +44.0% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with buyers in control | 47.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30) | 61.8 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($1.34 to $3.44) — its "stochastic" reading is 46 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 45.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.44 | $3.44 |
|---|---|---|
| From the 52-week high | it is 33.1% below its 52-week high (its highest price of the past year) | -33.1% |
| Above the 52-week low | it is 115.0% above its 52-week low (its lowest price of the past year) | +115.0% |
| Below the 52-week high | it is 33.1% below its highest point of the past year | 33.1% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $53.69 (set on 2021-02-11) | $53.69 |
| Given back of the 52-week move | over the past year its closes ranged ($1.11 to $2.87), and it has given back roughly a third of its rise from last year’s low — 32% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.73 to $1.78. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.4% |
| From the all-time high | it is 95.7% below its all-time high | -95.7% |
| Nearest price level | it is trading 18.6% below a resistance level at $2.73 — a price it turned at three times since 2024-11-07, most recently on 2026-01-23. Since 2024-10-08 it has 13 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +18.6% |
| All-time low | its lowest closing price on record is $0.8511 (set on 2025-05-28) | $0.8511 |
| Above the all-time low | it is 170.2% above its all-time low | +170.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2568 between its high and its low — about 11.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2568 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.74 and $2.96 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.74 – $1.85 – $2.96 |
| Typical daily range (% of price) | its price moves about 11.2% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 11.2% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges above its 200-day average price (44.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.78× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 3.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -3.3% |
|---|---|---|
| Open gap | it gapped 3.3% below the previous close today and has not traded back through the level it left behind at 2.72 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.3% |
| Gap filled | a 3.0% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 73.2 percentage points (the stock gained 74.2% while the market gained 1.0%) | +73.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 49.5 percentage points (the stock gained 53.3% while the market gained 3.8%) | +49.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 44.5 percentage points (the stock gained 62.0% while the market gained 17.5%) | +44.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 37.3 percentage points (the stock gained 52.3% while the market gained 15.0%) | +37.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: a "death cross" — its 50-day average is below its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 58% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.4% of the share price. | +58.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $1.75 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +31.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% above the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $1.93 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | +19.5% |
Price levels it has turned at before
PACB last closed at $2.30 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.73 | Resistance | 18.6% above the last close | turned there three times · 2024-11-07 to 2026-01-23 |
| $1.84 | Support | 20.0% below the last close | turned there twice · 2026-01-12 to 2026-07-02 |
| $1.80 | Support | 21.7% below the last close | turned there three times · 2024-12-18 to 2026-04-21 |
| $1.75 | Support | 23.7% below the last close | turned there five times · 2024-12-31 to 2026-06-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $1.25.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 16 trading days, since 2026-09-17.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · beating the market · Gapped down at the open (3%+) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.13 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$2.16 range $1.25 – $3.00; median $2.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PACB
- Consensus EPS estimate-$0.1286 next reporting period, as of 2026-10-04
- Estimate change, 30 days+$0.00118 from -$0.1298, on 2026-08-30, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Unprofitability and reliance on successfully scaling commercialization of HiFi sequencing platforms.","Significant leadership changes and potential for business disruption.","Dependence on sole-source suppliers for certain manufacturing components and sub-assemblies."]
What changed in the latest 10-Q
AI-assisted comparison of PACB's 10-Q filed 2026-05-08 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) references '2025 Annual Report filed with the U.S. Securities and Exchange Commission...on February 25, 2026' whereas older filing (2025-11-06) references '2024 Annual Report filed...on March 17, 2025'
- Newer filing adds specific mention of 'SPRQ-Nx chemistry' (versus 'SPRQ chemistry' in older filing)
- Newer filing adds strategic objective detail: 'Expand the capabilities of the Vega benchtop platform to broaden our market reach. We plan to enable faster run times and enhanced user experience through software improvements'
- Newer filing adds: 'Progress our clinical strategy to improve outcomes and create durability' with specific mention of 'in the Americas, where we continue to aggressively shift our strategy to clinical and commercial accounts where we believe the funding dynamics are more favorable'
- Newer filing adds strategic objective: 'Advance data-driven interpretation through scalable HiFi datasets and analytics' including reference to 'HiFi Solves Global Consortium'
- Newer filing reports Q1 2026 three-month results (March 31, 2026) with revenue of $37.2M, gross profit of $12.8M, operating loss of $8.4M, and cash/investments of $276.0M
- Newer filing reports litigation settlement expenses of $15.4 million in three months ended March 31, 2026
- Removed:
- Older filing (2025-11-06) contains reference to Nature Methods recognition of long-read sequencing as 'method of the year' for 2022, which is removed in newer filing
- Older filing references 'SMRT ® technology' in strategic context; newer filing does not include this trademark reference in comparable section
- Older filing lists 'four activities' for 2025 strategic objectives; newer filing lists 'five activities' for 2026 objectives
- Older filing reports Q3 2025 nine-month results (September 30, 2025); newer filing reports different period (Q1 2026 three-month results)
- Reworded:
- Older filing: 'Our products and technology, which include our HiFi long-read sequencing technology' changed to newer filing: 'Our products and technology, which primarily consist of our HiFi long-read sequencing systems'
- Older filing lists first objective as 'Enabling the full-scale release of the Vega benchtop platform'; newer filing addresses Vega as second objective with different scope and emphasis
- Older filing: 'Accelerating samples onto the Revio platform via SPRQ chemistry' changed to newer filing: 'Accelerate samples onto the Revio platform through SPRQ-Nx chemistry and application kits' with additional emphasis on cost reduction and efficiency
- Older filing references 'sub-$500 HiFi genome' metric; newer filing does not include this specific cost metric
- Older filing: objective order and emphasis differs; newer filing reorganizes four objectives into five with different strategic priorities
- Notes:
- The two filings cover different fiscal periods (Q3 2025 nine-month results versus Q1 2026 three-month results), so some financial metric changes reflect period differences rather than operational changes
- Text truncation in older filing's operating loss discussion prevents full comparison of that section
- Different fiscal year references (2025 Annual Report vs. 2024 Annual Report) reflect normal progression between filings
Risk Factors
- Added:
- Added risk factor in Summary section: 'the impact of the disposition of assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies could have on our business, financial condition and results of operations' (filed 2026-05-08)
- Removed:
- Removed reference to 'Onso, our SBB short-read platform' commercial shipments in 2023 from the 'Risks Related to Our Business' section (filed 2025-11-06)
- Reworded:
- Changed 'the impact of tariffs recently imposed by the U.S. government and its trading partners in response' to 'the impact of tariffs recently threatened or imposed by the U.S. government or its trading partners in response' in Summary Risk Factors (filed 2026-05-08)
- Removed bullet point text 'complete the scientific and technical validation of new products on our currently expected timeline or at all; deliver our future products in a timely manner to our customers; grow our market share by marketing and selling our products for new and addition' at end of Risks Related to Our Business section appears truncated in newer filing (filed 2026-05-08)
- Notes:
- The newer filing text appears truncated at the end of the provided excerpt, making full comparison of subsequent risk factor details not fully assessable
- The removal of Onso references aligns with the new risk factor addition regarding 'disposition of assets related to short-read DNA sequencing technology,' suggesting a business transaction occurred between filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 1 sell ($2M) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 2 sells ($2M) — 2 selling insiders
- Last 180 days · read to 2026-10-040 buys · 2 sells ($2M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-06. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PACB's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
7 institutional 13F filers reported holding PACB as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 75,220,250
- Reported value $126,370,019
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 2 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PACB's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PACB had 48,892,225 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
PACB had 15.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.49 days to cover at the same settlement.
- Reported short interest (shares) 48,892,225
- Short interest (% of shares outstanding) 15.7%
- Prior settlement (shares) 49,578,770
- Reported change -1.38%
- Days to cover (reported) 10.49
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PACB vs…
PACIFIC BIOSCIENCES OF CALIFORNIA is found in…
PACB ranks in…
Frequently asked questions
What does PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) do?
PacBio is a life science technology company that designs, develops, and manufactures advanced long-read genomic sequencing systems. Its technology enables scientists and clinical researchers to gain comprehensive and accurate insights into genomes, transcriptomes, and epigenomes to address complex genetic challenges in areas such as rare disease, oncology, and infectious disease.
What sector is PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) in?
PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) is classified in the Health Care sector. Its industry is genomic sequencing instruments. It trades on NASDAQ.
Who are PACIFIC BIOSCIENCES OF CALIFORNIA's (PACB) competitors?
Notable peers of PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) include Illumina, Oxford Nanopore Technologies, 10x Genomics and Thermo Fisher Scientific. This peer set is informational only — not financial advice.
Is PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) overbought or oversold right now?
PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 62, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PACB come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.